Allergy Pollen
0
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
InmunotekSpain - Madrid
2 programsAllergenic extractN/A1 trial
Allergenic extractsN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
InmunotekAllergenic extracts
InmunotekAllergenic extract
Allergy TherapeuticsSpiriplex Allergenex Microassay
Clinical Trials (3)
Total enrollment: 161 patients across 3 trials
Phleum Pratense and Dactylis Glomerata Allergen Extracts Standardization
Start: Dec 2024Est. completion: Jan 202531 patients
N/ACompleted
Juniperus Oxycedrus and Cupressus Arizonica Allergen Extracts Standardisation.
Start: Oct 2023Est. completion: Jan 202430 patients
N/ACompleted
Microassay and Allergy Skin Prick Test Correlation Study
Start: Apr 2018Est. completion: Jun 2019100 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.